On July 21, 2026, Bluejay Diagnostics announced the completion of patient enrollment for its SYMON-II multicenter clinical validation study ahead of schedule. The study enrolled 750 patients to evaluate the Symphony IL-6 test's ability to assess 28-day all-cause mortality risk in sepsis patients admitted to the ICU. Preliminary observations show an approximately 17% 28-day mortality rate. The company intends to use the resulting clinical dataset to support future FDA 510(k) regulatory submissions and commercialization of the Symphony platform. The company operates in the medical diagnostics industry, developing rapid, near-patient diagnostic technologies for critical care.

Bluejay Diagnostics, Inc. stockholders at the June 9, 2026 annual meeting approved an amendment to the 2021 Stock Plan to increase the number of shares reserved for issuance by 600,000. Stockholders also approved an amendment to the certificate of incorporation to authorize a reverse stock split of between 1-for-2 and 1-for-20, with the board of directors to determine the final ratio and timing (no later than June 9, 2027) at its discretion. Bluejay Diagnostics, Inc. is a diagnostics company.

Bluejay Diagnostics, Inc. closed a private placement of pre-funded warrants, Series G warrants, and Series H warrants, receiving approximately $7.7 million in proceeds. The securities were sold at a combined price of $2.324 per warrant package.